Biogen isn't concerned about competing with Eli Lilly in the Alzheimer’s drug space, CEO says

Biogen CEO Christopher Viehbacher said during an earnings call that Eli Lilly needs to consider maintenance doses its Alzheimer's treatment donanemab.